Possible Concomitant Aggressive NK Cell Leukemia and EBV-positive T-cell lymphoma; Using the online beta version of WHO-HAEM5 and videoconferencing software to make diagnoses accessible in an emerging economy.
Aggressive NK Cell leukemia, chronic active EBV disease
Diagnostic hematopathology in emerging economies
Hemophagocytic lymphohistiocytosis, UNC13D
Systemic EBV-positive T-cell lymphoma of Childhood
Telepathology
WHO-HAEM5 classification (beta version online)
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
15
07
2023
accepted:
22
09
2023
medline:
9
10
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
Using the World Health Organization Classification 5th edition (beta version online; WHO-HAEM5bv) in emerging economies is key to global healthcare equity. Although there may be ongoing updates, hesitancy in accepting and reporting these diagnoses in publication conflicts with the WHO's commitment to global accessibility. Aggressive NK cell leukemia (ANKL) and systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL) with CD4-positive immunophenotype are both rare entities, are most described in Asians and East Asians, are associated with prior systemic chronic active EBV disease (CAEBV), and presentation with Hemophagocytic Lymphohistiocytosis (HLH). Recognizing and diagnosing any one of these entities requires not only training and experience in hematopathology, but good cooperation between clinical physicians and all areas of the laboratory. We describe a 30-year-old woman who presented to a Vietnam hospital and was rapidly diagnosed with ANKL, SEBVTCL, and HLH using WHO-HAEM5bv essential criteria, aided by expert consultation from a United States (US) board certified hematopathologist in real-time using video conferencing software. Zoom™ videoconferencing software; Immunohistochemistry; flow cytometric immunophenotyping; polymerase chain reaction (PCR), Next Generation Sequencing (NGS). At the time of hospital admission, automated complete blood count (CBC) with differential count showed slight anemia, slight lymphocytosis, and moderate thrombocytopenia. HIV serology was negative. Whole blood PCR for EBV was positive showing 98,000 copies/ml. A lymph node biopsy revealed histology and immunohistochemistry consistent with the online beta version WHO-HAEM5 classification of SEBVTCL arising in CAEBV. Blood and bone marrow studies performed for staging revealed no histologic or immunohistochemical evidence of T-cell lymphoma in the bone marrow core, however, atypical blood smear lymphocyte morphology and blood immunophenotyping by flow cytometry were consistent with WHO-HAEM5 classification of ANKL. NGS revealed no evidence of genetic variant(s) associated with HLH in Vietnam. All laboratory studies were performed at Blood Transfusion Hematology Hospital (BTHH) in Ho Chi Minh City Vietnam. Although Vietnam, an emerging economy, currently lacks the laboratory infrastructure to more rigorously confirm a rare synchronous presentation of two distinct EBV-driven T/NK cell neoplasms, these two concomitant diagnoses were made using only laboratory techniques available in Vietnam with the help of WHO-HAEM5bv and real-time video consultation by a US hematopathologist.
Sections du résumé
BACKGROUND
BACKGROUND
Using the World Health Organization Classification 5th edition (beta version online; WHO-HAEM5bv) in emerging economies is key to global healthcare equity. Although there may be ongoing updates, hesitancy in accepting and reporting these diagnoses in publication conflicts with the WHO's commitment to global accessibility. Aggressive NK cell leukemia (ANKL) and systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL) with CD4-positive immunophenotype are both rare entities, are most described in Asians and East Asians, are associated with prior systemic chronic active EBV disease (CAEBV), and presentation with Hemophagocytic Lymphohistiocytosis (HLH). Recognizing and diagnosing any one of these entities requires not only training and experience in hematopathology, but good cooperation between clinical physicians and all areas of the laboratory. We describe a 30-year-old woman who presented to a Vietnam hospital and was rapidly diagnosed with ANKL, SEBVTCL, and HLH using WHO-HAEM5bv essential criteria, aided by expert consultation from a United States (US) board certified hematopathologist in real-time using video conferencing software.
METHODS
METHODS
Zoom™ videoconferencing software; Immunohistochemistry; flow cytometric immunophenotyping; polymerase chain reaction (PCR), Next Generation Sequencing (NGS).
RESULTS
RESULTS
At the time of hospital admission, automated complete blood count (CBC) with differential count showed slight anemia, slight lymphocytosis, and moderate thrombocytopenia. HIV serology was negative. Whole blood PCR for EBV was positive showing 98,000 copies/ml. A lymph node biopsy revealed histology and immunohistochemistry consistent with the online beta version WHO-HAEM5 classification of SEBVTCL arising in CAEBV. Blood and bone marrow studies performed for staging revealed no histologic or immunohistochemical evidence of T-cell lymphoma in the bone marrow core, however, atypical blood smear lymphocyte morphology and blood immunophenotyping by flow cytometry were consistent with WHO-HAEM5 classification of ANKL. NGS revealed no evidence of genetic variant(s) associated with HLH in Vietnam. All laboratory studies were performed at Blood Transfusion Hematology Hospital (BTHH) in Ho Chi Minh City Vietnam.
CONCLUSION
CONCLUSIONS
Although Vietnam, an emerging economy, currently lacks the laboratory infrastructure to more rigorously confirm a rare synchronous presentation of two distinct EBV-driven T/NK cell neoplasms, these two concomitant diagnoses were made using only laboratory techniques available in Vietnam with the help of WHO-HAEM5bv and real-time video consultation by a US hematopathologist.
Identifiants
pubmed: 37803436
doi: 10.1186/s13000-023-01395-9
pii: 10.1186/s13000-023-01395-9
pmc: PMC10557268
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63 .
Suzuki R, Ott G, Takeuchi K et al. Aggressive NK cell Leukemia. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63 .
Chng WJ, Wood BL. EBV-positive T-cell and NK-cell lymphoid proliferations and lymphomas of childhood. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63 .
Araujo I, Sangueza OP, Kimura H, Liu W-P. Systemic chronic active EBV disease. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63 .
Marcogliese N, Sangueza JM, Ng S-B et al. Systemic EBV-positive T-cell lymphoma of childhood. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63 .
Xinh PT, Chuong HQ, Diem TPH, Nguyen TM, et al. Spectrum mutations of PRF1, UNC13D, STX11, and STXBP2 genes in vietnamese patients with hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2021;43:1524–30.
doi: 10.1111/ijlh.13674
pubmed: 34339548
Kwon Y-K, Kim WS, Lim ST, Kim SJ, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(15):2973–80.
doi: 10.1182/blood-2012-05-431460
Dayton VJ, Nguyen CK, Van TT, Nguyen VT, et al. Evaluation of opportunities to improve hematopathology diagnosis for Vietnam pathologists. Am J Clin Path. 2017;148(6):529–37.
doi: 10.1093/ajcp/aqx108
pubmed: 29140404
Vitkovski T, Bhuiya T, Esposito M. Utility of telepathology as a consultation tool between an off-site surgical pathology suite and affiliated hospitals in the frozen section diagnosis of lung neoplasms. J Pathol Inform. 2015;1:55–9.
doi: 10.4103/2153-3539.168515
Strauss SE, Tosata G, Armstrong G, Lawley T, et al. Ann Int Med. 1985;102:7–16.
doi: 10.7326/0003-4819-102-1-7
Kikuta H, Taguchi Y, Tomizawa K, Kojima K, et al. Epstein-Barr virus genome-positive T-lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like illness. Nature. 1988;333(2):455–7.
doi: 10.1038/333455a0
pubmed: 2836734
Ishihara S, Tawa A, Yumura-Yagik, Murata M, et al. Cloncal T-cell lymphoproliferation containing Epstein-Barr (EB) virus DNA in a patient with chronic active EB virus infection. Japan J Cancer Res. 1989;80:99–101.
doi: 10.1111/j.1349-7006.1989.tb02273.x
Kanegana H, Bhatia K, Gutierrez M, Kaneda H, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood. 1998;91(6):2085–91.
doi: 10.1182/blood.V91.6.2085
Cohen JI, Jaffe ES, Dale JK, Pittaluga S, et al. Characterization and treatment of chronic active Epstein-Barr virus in the United States. Blood. 2011;117(22):5835–49.
doi: 10.1182/blood-2010-11-316745
pubmed: 21454450
pmcid: 3112034
Quintanilla-Martinez L, Ko Y-H, Kimura H, Jaffe ES. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris HL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. International Agency for Research on Cancer; Lyon, France; 2017. Revised 4th Edition.
Smith MC, Cohen DN, Grieg B, Yenamandra A, et al. The ambiguous boundary between EBV-related hematophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder. Int J Exp Pathol. 2014;7(9):5738–49.
Yones I, Sakashita C, Imadome K-I, Kobyashi T, et al. Nationwide survey of chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918–26.
doi: 10.1182/bloodadvances.2020001451
Fujimoto A, Ishida F, Izutsu K, Yamasaki S. Allogeneic stem cell transplants for patients with aggressive NK-cell leukemia. Bone Marrow Transplant. 2021;56:347–56.
doi: 10.1038/s41409-020-01009-8
pubmed: 32778688
Hamadani M, Kanate AS, DiGillio A, Ahn KW, et al. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia; a CIBMTR analysis. Biol Blood Marrow Transplantation. 2017;23(5):853–6.
doi: 10.1016/j.bbmt.2017.01.082